Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2009. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share plan transactions.
Specific transaction details include:
- Transaction Type: Increase in notional interests in Ordinary shares and Ordinary Share ADRs.
- Trigger Event: Notional re-investment of the dividend paid to shareholders on October 8, 2009.
- Share Prices: Ordinary shares at £12.35 per share; Ordinary Share ADRs at $39.58 per ADR.
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It solely documents the administrative update of notional share holdings for specific individuals following the dividend reinvestment.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three-year measurement period.
Key Facts for Investor Verification
- Verify the vesting schedule and conditions for the GlaxoSmithKline Performance Share Plan to understand future payout obligations.
- Confirm the total number of notional shares held by the listed directors and managers to assess potential future dilution or voting power upon vesting.
- Review the dividend payment date of October 8, 2009, to correlate with the share price used for the notional reinvestment.